Abstract: Provided are a stable pharmaceutical composition of an anti-IL-17A antibody and an application thereof in medicine. The pharmaceutical composition contains an anti-IL-17A antibody or an antigen-binding fragment thereof, and a buffer, can further contain at least one stabilizer, and can further contain a surfactant.

Abstract: A method for designing a phase-typed diffraction suppressing optical device (12) for a transparent display screen(11) is disclosed, which comprises: acquiring a light field complex amplitude distribution U(x2,y2,d)=A(x2,y2,d)exp(i?20(x2,y2,d)) on a plane with a distance d from the transparent display screen (12) after a plane wave is transmitted through the screen; and designing the diffraction suppressing optical device (12), so that it has a transmittance function t2 (x2,y2)=exp(i?21(x2,y2)) and satisfies ?20 (x2,y2,d)+?21 (x2,y2)=C, where C is a constant. A diffraction suppressing optical device (12) and an under-screen camera apparatus (1) comprising the same are disclosed. The phase-typed diffraction suppressing optical device (12) suppresses the diffraction effect in the under-screen camera apparatus (1) by providing phase modulation, thereby improving the quality of under-screen imaging.

Abstract: Various examples are directed to systems and methods for monitoring a plurality of container-implemented software application instances. A first ping agent executing in an orchestration container may launch a worker process in the orchestration container. The worker process may launch first and second worker threads in the orchestration container. The first worker thread may send a first ping message to a first application instance executing in a first application container outside the orchestration cluster. The second worker thread may send a second ping message to a second application instance executing in a second application container outside the orchestration cluster.

Abstract: The invention provides a method for designing a diffractive optical element, characterized in comprising: S101: obtaining a first optical field pattern on a target plane; S102: converting the first optical field pattern on the target plane into a second optical field pattern on a spherical surface; S103: compensating for missing points of the second optical field pattern on the spherical surface, and matching grayscale values, so as to obtain a corrected third optical field pattern; and S104: obtaining a phase distribution of the diffractive optical element according to the third optical field pattern. By means of the design method, the projection quality of a diffractive optical element is improved.

Abstract: Some embodiments include a system, method, and non-transitory medium, with the system including an interface to at least one database product; a stateless ping operator to manage lifecycle events associated with the at least one database product; and a first product-specific ping agent to determine an availability of and generate metrics associated with a plurality of instances of a first specific database product of the at least one database product monitored by the first product-specific ping agent, the first product-specific ping agent receiving an assignment of the plurality of instances of the first specific database product to monitor from the ping operator.

Abstract: The present invention provides a stable pharmaceutical composition comprising an anti-BTLA (B and T lymphocyte attenuator) antibody and use thereof in medicines. The pharmaceutical composition comprises an anti-BTLA antibody and a buffer, further comprises at least one stabilizer, and optionally further comprises a surfactant.

Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.

Abstract: A method for designing a phase-typed diffraction suppressing optical device (12) for a transparent display screen (11) is disclosed, which comprises: acquiring a light field complex amplitude distribution U(x2,y2,d)=A(x2,y2,d)exp(i?20(x2,y2,d)) on a plane with a distance d from the transparent display screen (12) after a plane wave is transmitted through the screen; and designing the diffraction suppressing optical device (12), so that it has a transmittance function t2 (x2,y2)=exp(i?21(x2,y2)) and satisfies ?20 (x2,y2,d)+?21 (x2,y2)=C, where C is a constant. A diffraction suppressing optical device (12) and an under-screen camera apparatus (1) comprising the same are disclosed. The phase-typed diffraction suppressing optical device (12) suppresses the diffraction effect in the under-screen camera apparatus (1) by providing phase modulation, thereby improving the quality of under-screen imaging.

Abstract: Disclosed in the present disclosure is an FPGA implementation device and method for an FBLMS algorithm based on block floating point. The method includes: blocking, caching, and reassembling a reference signal, by an input caching and converting module, converting into a block floating point system and performing FFT; filtering, by a filtering module, in a frequency domain and performing dynamic truncation; caching, by an error calculating and output caching module, a target signal on a block basis, converting into a block floating point system, subtracting an output result output from the filtering module from the converted target signal to obtain an error signal, converting the error signal into a fixed point system to obtain a final cancellation result; obtaining, by a weight adjustment amount calculating module and a weight updating and storing module, an adjustment amount of a frequency domain block weight and updating the frequency domain block weight.

Abstract: The present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a malignancy. In particular, the present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a sarcoma, alveolar soft part sarcoma, angiosarcoma and undifferentiated polymorphic sarcoma, and use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of lymphoma.

Abstract: The present disclosure relates to use of an anti-PD-1 antibody in the treatment of melanoma. The present disclosure also relates to use of an agent for detecting BRAF, NRAS, and CDK4/CCND1 gene mutations in a detection kit for predicting the therapeutic effect of an anti-PD-1 antibody and/or an antigen-binding fragment thereof administered alone to a patient with melanoma.

Abstract: In a method for embedding user information in webpages, user information of a user who logs into a target website is obtained. The user information is converted into color values. The color values are embedded in a target webpage of the target website. If a webpage is leaked, a user who leaks the webpage can be traced.

Abstract: The present disclosure relates, according to some embodiments, to a method of determining a quantitatively measured photoprotection of a photoprotective composition, the method comprising: (a) distributing the photoprotective composition in a position in between a drawdown bar and at least one substrate to produce a distributed photoprotective composition; (b) drawing down the distributed photoprotective composition to a thickness on at least one substrate to produce a drawn down sample film; (c) drying the drawn down sample film to produce a dried sample film; (d) measuring a UV absorption of the dried sample film to produce a UV absorption spectrum; (e) determining the quantitatively measured photoprotection of the photoprotective composition from the UV absorption spectrum.

Abstract: In a method for embedding user information in webpages, user information of a user who logs into a target website is obtained. The user information is converted into color values. The color values are embedded in a target webpage of the target website. If a webpage is leaked, a user who leaks the webpage can be traced.

Abstract: There are provided bivalent compounds and conjugates thereof, the conjugates comprising a bivalent compound, a targeting moiety, and a bioactive agent, as well as pharmaceutical compositions and methods of use of the conjugate for the treatment, inhibition, or prevention of diseases and disorders which are therapeutic targets of the bioactive agent.

Abstract: Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.

Abstract: The present invention provides an image processing circuit for compensating image data for a display panel used for displaying first and second image patterns respectively having first and second current loadings. The image processing circuit is used for: receiving a first original image data of the first image pattern and a second original image data of the second image pattern having the same brightness value for a pixel at the same location; converting the first original image data into a first final image data to compensate for an IR drop according to the first current loading; and converting the second original image data into a second final image data to compensate for the IR drop according to the second current loading. The first final image data and the second final image data have substantially the same brightness value for the pixel at the same location.

Abstract: A method and device for implementing an FPGA-based large-scale radio frequency interference array correlator are provided. The method includes: obtaining the number of channels of data of a radio frequency interference array, and performing average division; calculating the total correlation of data group and the total correlation between the data group and other data groups respectively through corresponding correlation calculation modules, and performing an accumulation calculation in an integration period to complete the total correlation operation of the radio frequency interference array. By means of grouping division and time division multiplexing, the FPGA resource is effectively utilized, and the calculation process of FPGA is simplified. The new method is suitable for the operation process of the system with high parallelism and high real-time requirements, and provides a high-efficiency solution for the real-time calculation of massive data of the large-scale radio frequency interference array.

Abstract: A bifunctional nucleoside hydrogel is formed by dissolving isoguanosine, guanosine and a borate in water or an aqueous solution and then crosslinking same. The bifunctional nucleoside hydrogel integrates a carrier and a drug effect and has a significant inhibitory effect on the activity of tumor cells, and in particular has a significant inhibitory effect on the activity of cells related to lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma and tongue squamous cell carcinoma, of which the inhibitory effect on the activity of cells related to oral squamous cell carcinoma is the best. Therefore, the bifunctional nucleoside hydrogel has potential application prospects in preparing anti-tumor drugs, and particularly, same can provide a new approach for treating oral squamous cell carcinoma.